Abstract 38P
Background
Regulatory T cells (Treg) play a crucial role as prognostic factors and intervention targets for isocitrate dehydrogenase (IDH)-wild type (wt) glioblastoma (GBM). The study aimed to construct a model predicting the Treg infiltration in IDH-wt GBM patients using pathomics techniques and explore related biological processes.
Methods
Flow cytometry was used to detect the proportion of Treg in orthotopic mouse glioblastoma brain tissue. Clinical data of IDH-wt GBM patients from the TCGA database were analyzed retrospectively. Features were extracted from HE-stained biopsy sections using the Pyradiomics package. The pathomics model was constructed using the Gradient Boosting Machine algorithm after performing feature selection with mRMR and Relief algorithms. Cox proportional hazard regression analysis was employed to access the association between pathomics score (PS) and overall survival (OS). Transcriptomic data were analyzed through GSEA set enrichment, differential gene expression, and correlation analyses.
Results
The study established a pathomics model with 3 pathomics features that effectively predicted Treg infiltration (Training set: AUC=0.807; Validation set: AUC=0.735). PS positively correlated with high Treg expression. Survival analysis indicated that patients with high PS had significantly lower OS than the low PS group (median survival time: 12.0 vs 14.4 months; p=0.009). Multivariate COX analysis revealed that high PS expression independently served as a prognostic risk factor for IDH-wt GBM patients (HR, 2.16; 95% CI, 1.269-3.677; p=0.005). Subgroup analysis showed that high PS was a risk factor for OS in patients receiving chemotherapy (HR, 2.232; 95% CI, 1.309-3.905; p=0.003) or radiotherapy (HR, 1.882; 95% CI, 1.161-3.049; p=0.01).GSEA enrichment analysis revealed significant associations of PS with the NOTCH, IL-6/JAK/STAT3 signaling pathways. High PS significantly correlated with elevated RAD50 expression.
Conclusions
The developed pathomics model, based on machine learning algorithms, can noninvasively predict Treg infiltration and prognosis in IDH-wt GBM patients. The biological processes related to the model may involve RAD50 and pathways, including NOTCH, IL-6/JAK/STAT3.
Legal entity responsible for the study
The authors.
Funding
The Joint Funds for the Innovation of Science and Technology, Fujian Province (No.2021Y9301).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
90P - HAIC plus sintilimab and bevacizumab biosimilar as treatment for patients with advanced hepatocellular carcinoma (HCC): a phase II trial
Presenter: HAIBIN ZHANG
Session: Poster Display
91P - A real-world study of tislelizumab (Anti-PD-1) plus tyrosine kinase inhibitors for intermediate or advanced hepatocellular carcinoma
Presenter: Wei zhang
Session: Poster Display
92P - TAE-HAIC plus lenvatinib and PD-1 inhibitors versus TAE-HAIC plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: A propensity score matching study
Presenter: hongjie Cai
Session: Poster Display
93P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: a real-world, retrospective, multicentric study.
Presenter: Margherita Rimini
Session: Poster Display
94P - First-line chemotherapy plus immunotherapy versus chemotherapy alone for advanced gallbladder carcinoma
Presenter: Qin-qin Liu
Session: Poster Display
95P - A single-arm, multicenter phase ? trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Junsheng Wang
Session: Poster Display
97P - ICI for patients with MSS metastatic colorectal cancer
Presenter: Zayana Sangadzhieva
Session: Poster Display
Resources:
Abstract
99P - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer
Presenter: Hongnan Mo
Session: Poster Display
100P - Phase II trial of tislelizumab plus bevacizumab and chemotherapy as the first-line therapy for persistent, recurrent, or metastatic cervical cancer: updated efficacy and safety results
Presenter: Jianqing Zhu
Session: Poster Display